# Neoadjuvant Therapy With Toripalimab and JS004 Combined With Etoposide and Platinum Chemotherapy for Limited-stage Small Cell Lung Cancer : A Phase 2 Trial

> **NCT06256237** · PHASE2 · RECRUITING · sponsor: **Shanghai Pulmonary Hospital, Shanghai, China** · enrollment: 30 (estimated)

## Conditions studied

- Limited Stage Small Cell Lung Cancer

## Interventions

- **DRUG:** JS004
- **DRUG:** Toripalimab
- **PROCEDURE:** surgery
- **DRUG:** Etoposide
- **DRUG:** Platinum

## Key facts

- **NCT ID:** NCT06256237
- **Lead sponsor:** Shanghai Pulmonary Hospital, Shanghai, China
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-04-01
- **Primary completion:** 2027-01-31
- **Final completion:** 2032-01-31
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2024-05-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06256237

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06256237, "Neoadjuvant Therapy With Toripalimab and JS004 Combined With Etoposide and Platinum Chemotherapy for Limited-stage Small Cell Lung Cancer : A Phase 2 Trial". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06256237. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*